Jul. 24 at 4:25 AM
$SLXN undervalued at
$0.88 pre-split (
$13.20 post-1-for-15 reverse split ) with an
$8.9M market cap. A risk-adjusted DCF projects a
$1.5B acquisition value post-Phase 3 success, equating to
$68.65 post-split (~
$4.58 pre-split). Instead of a single
$55M capital raise, hypothetical multi-stage raises at potentially higher valuations as clinical risks decrease could optimize funding. Early raises at
$0.88 would support trials through 2028, with later rounds at higher valuations reflecting milestone progress, reducing dilution. Promising preclinical data and H2 2025 milestones should drive stock appreciation. The year-end target remains
$4.00 pre-split (
$60 post-split), offering a 4.5x risk adjusted return. This suggests a ~2.7x upside from the current
$13.20 post-split price. Improved clinical outcomes or market sentiment could further boost upside. All figures are post-split; the
$35.50 risk-adjusted value equals ~
$2.37 pre-split. SLXN’s high-risk, high-reward profile persists.
